|
|
|
|
Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumours that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more...
|
|
|
Pediatric cancers enter the whole-genome sequencing pipeline with the initiation of the St. Baldricks proje
Hogarty is a pediatric oncologist with clinical expertise in neuroblastoma, germ cell tumors, and histiocytic disorders.He is an attending physician at CHOP and an associate professor of pediatrics at the University of Pennsylvania School of Medicine. A...
|
|
|
Human mesenchymal stem cells and their use in cell-based therapies
The human population is increasingly facing various diseases, including types of cancer, that cannot be cured with conventional drugs.Advanced drug targeting of tumor cells is also often impossible when treating highly invasive and infiltrative tumors such...
|
|
|
New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile
Modern Pathology advance online publication, March 19, 2010.doi:10.1038/modpathol.2010. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile.
|
|
|
Lixte Biotechnology Holdings, Inc. - Strategic Analysis Review - new market report published
Lixte Biotechnology Holdings, Inc.- Strategic Analysis Review Summary The Lixte Biotechnology Holdings, Inc. - Strategic Analysis Review is an in-depth business and strategic analysis of Lixte Biotechnology Holdings, Inc.. The report provides a...
|
|
|
ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer
Therapeutics Breaking News News source: Business Wire ImmunoCellular Therapeutics, Ltd.(OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of...
|
|
|
Lymphoma Tumor Suppressor Enhances Growth of Brain Tumors
While the A20 protein (tumor necrosis factor, alpha-induced protein 3 or TNFAIP3) is known to be tumor suppressive in lymphoma, a recent study has found that in glioblastoma, an aggressive type of brain tumor, A20 acts as a potent tumor enhancer....
|
|
|
Cancer Gene Therapy: Investigators at University of Chicago, Brain Tumor Center have published new data on cancer gene therapy
Today's Medical & Research News Investigators at University of Chicago, Brain Tumor Center have published new data on March 17th, 2010 Printer-Friendly Version City:Chicago State:IL Country:United States Biotechnology Brain Cancer Brain Carcinoma Drug...
|
|
|
ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer
ICT-109 and ICT-37 are humanized monoclonal antibodies that target small cell lung cancer and pancreatic cancer.ICT-109 antibody specifically binds to certain glycosylations (sugar structures) present on CEA-CAM6 and CEA-CAM5, which are highly expressed on...
|
|
|
ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer
LOS ANGELES(BUSINESS WIRE) ImmunoCellular Therapeutics, Ltd.(OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United...
|
|
|
ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer
(BUSINESS WIRE) ----ImmunoCellular Therapeutics, Ltd.(OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States...
|
|
|
ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer
(BUSINESS WIRE) ----ImmunoCellular Therapeutics, Ltd.(OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States...
|
|
|
ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer
(BUSINESS WIRE) ----ImmunoCellular Therapeutics, Ltd.(OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States...
|
|
|
ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer
ImmunoCellular Therapeutics, Ltd.(OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark...
|
|
|
ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer
ImmunoCellular Therapeutics, Ltd.(OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark...
|
|
|
Brain tumour growth switch discovered
Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die.When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more. Researchers at the Ohio State University...
|
|
|
Levitate cancer cells for rapid 3D tissue
For similar stories, visit the Cancer Topic Guide Iron-rich cells that grow into balls when "levitated" by magnets could provide a new way to study cancer in the lab and produce replacement tissue for grafts.The magnets can sculpt balls into shapes that...
|
|
|
Mapping Out a Plan of Attack
The Cancer Genome Atlas Provides Repository for Data, Discoveries The Cancer Genome Atlas (TCGA) is a comprehensive effort to create a data repository for the discoveries and findings of more than 150 of the nations top researchers who are working in concert on...
|
|
|
Discovery of MiR-451 molecule may serve as a biomarker for brain tumor
Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die.When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more. Researchers at the Ohio State University...
|
|
|
YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
- University of Toronto - Interaction of nimotuzumab with EGFRvIII, a mutant form of EGF receptor frequently expressed in brain tumors - MISSISSAUGA, ON The poster entitled '111In-NLS-Nimotuzumab: A potent Auger electron-emitting radiotherapeutic agent for EGFR...
|
|
|
YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Companies: Related QuotesSymbolPriceChangeYM.TO1.160.00{'s' : 'ym.to,ymi','k' : 'c10,l10,p20,t10','o' : '','j' : ''} Press Release Source: On Monday March 15, 2010, 7:30 am - University of Toronto - Interaction of nimotuzumab with EGFRvIII, a mutant form of EGF...
|
|
|
Researchers Discover Brain Tumor's EURGrow-or-GoEUR Switch
COLUMBUS, Ohio?Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die? When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more. Researchers at the Ohio...
|
|
|
Integrin Inhibitors For Targeting Cancer
This diagram represents the hypothetical mechanism of action for cilengitide (EMD 121974) that is currently the subject of clinical trials (Phase II, III).It is not intended to convey any inferences or conclusions regarding the safety or effectiveness of the...
|
|
|
'Grow-or-go' Switch Found for Brain Tumor
The brain tumor switch responsible for the 'grow-or-go' phenomenon has been discovered by American researchers.Cancer cells in brain tumors have to adjust to periods of low energy or die. When energy levels are high, tumor cells grow and multiply but when...
|
|
|
Discovery Of Brain Tumor's 'Grow-Or-Go' Switch
Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die.When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more. Researchers at the Ohio State University...
|
